HARVEST TRAVEL & LEISURE INCOME ETF UNIT CL A
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2011-01-01
- Employees
- 25
- Market Cap
- $211.2M
- Introduction
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in March 2011 and is headquartered in New Haven, CT.
Clinical Trials
27
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (25 trials with phase data)• Click on a phase to view related trials
NAL ER IPF Respiratory Function and Safety Study
- First Posted Date
- 2025-06-25
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Trevi Therapeutics
- Target Recruit Count
- 10
- Registration Number
- NCT07036029
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇬🇧Medicines Evaluation Unit Ltd., Manchester, United Kingdom
A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2025-06-11
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Trevi Therapeutics
- Target Recruit Count
- 115
- Registration Number
- NCT07015398
Refractory Chronic Cough Improvement Via NAL ER (RIVER)
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Trevi Therapeutics
- Target Recruit Count
- 66
- Registration Number
- NCT05962151
- Locations
- 🇬🇧
Egin Research Ltd, High Wycombe, United Kingdom
🇨🇦McMaster University Medical Centre, Hamilton, Ontario, Canada
🇨🇦Inspiration Research, Toronto, Ontario, Canada
Cough Reduction in IPF With Nalbuphine ER
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Trevi Therapeutics
- Target Recruit Count
- 165
- Registration Number
- NCT05964335
- Locations
- 🇬🇧
Queen Elizabeth Hospital Birmingham - University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
🇦🇺Eastern Health-Box Hill Hospital, Box Hill, Australia
🇦🇺Concord Repatriation General Hospital, Concord, Australia
A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough
- First Posted Date
- 2019-07-23
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Trevi Therapeutics
- Target Recruit Count
- 42
- Registration Number
- NCT04030026
- Locations
- 🇬🇧
09, Cambridge, United Kingdom
🇬🇧08, Cottingham, United Kingdom
🇬🇧17, Dundee, United Kingdom
- Prev
- 1
- 2
- 3
- Next
News
Stifel Raises Price Target on Trevi Therapeutics as Haduvio Shows Promise for Chronic Cough Treatment
Stifel investment bank has increased its price target for Trevi Therapeutics (TRVI) from $8 to $12, maintaining a Buy rating as the company approaches key trial data readout.
Trevi Therapeutics' Haduvio Shows Promise for IPF-Related Cough Treatment, Receives Buy Rating
Leerink Partners analyst maintains a Buy rating for Trevi Therapeutics with a $7.00 price target, citing Haduvio's potential in treating idiopathic pulmonary fibrosis (IPF) cough.
Trevi Therapeutics' Haduvio Phase 2b Trial for IPF-Related Chronic Cough Nears Completion
Trevi Therapeutics' Phase 2b CORAL trial evaluating Haduvio for chronic cough in IPF patients has reached 75% enrollment, indicating strong progress.
Trevi Therapeutics' Oral Nalbuphine Demonstrates Reduced Abuse Potential in Clinical Study
• Trevi Therapeutics' oral nalbuphine showed statistically significant lower "Drug Liking" compared to IV butorphanol in a human abuse potential (HAP) study. • The study assessed three doses of oral nalbuphine (81mg, 162mg, 486mg) against IV butorphanol and placebo in recreational drug users. • Secondary endpoints were consistent with the primary endpoint, with no serious adverse events reported during the study. • These results support nalbuphine's potential as a non-scheduled option for chronic cough without the abuse risks of traditional opioids.
Trevi Therapeutics Announces Clinical Trial Progress for Haduvio in Chronic Cough
Trevi Therapeutics' Phase 2b CORAL trial for chronic cough in IPF reaches 50% enrollment; sample size re-estimation results are expected in December 2024.